Michelle Min is a Dermatology physician affiliated with University of California, Irvine. OpenAlex indexes 66 publications with 773 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
118 Med Surg I
Irvine, CA 926972907
Telephone
949-824-0606Provider last certified this registry record 22 Feb 2025.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202514 payments$19,817openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202518 payments$10,784openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33.9%Corticosteroid14.9%Triamcinolone Acetonide62%Triamcinolone acetonide38%Part D + Part B≥76 patientsInterleukin-4 Receptor alpha Antagonist12.2%Dupixent Pen62%Dupixent Syringe39%Part D<11 patients+ 4 more classes in this area
Anti-infectives
16%Azole Antifungal13.1%Ketoconazole92%Fluconazole8%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor1.5%Valacyclovir100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
13.7%Calcineurin inhibitor3.2%Tacrolimus100%Part D≥20 patientsNucleoside Metabolic Inhibitor2.7%Fluorouracil100%Part D≥25 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology
2026 - Early onset gastric cancer: clinical and molecular insights into a rising epidemic among younger adults
Baylor University Medical Center Proceedings
2025 - Sex Differences in Outcomes After Tenecteplase for Minor Stroke: A Subanalysis of the TEMPO‐2 Trial
Journal of the American Heart Association
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Mitchell Brin, MD
University of California, Irvine
Deborah Wing, MD
University of California, Irvine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”